Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 783-785

  Rutschmann, O T ^a   Negro, F ^b   Hirschel, B ^b   Hadengue, A ^b   Amvar, D ^b   Perrin, L H ^b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RNA ANALYSIS; SUPERINFECTION; VIREMIA;

EID: 0031912330     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517808     Document Type: Article

References (10)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunode ficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997:337:725-33.
2. Chamot E, de Saussure P, Hirschel B, Déglon JJ, Perrin LH. Incidence of hepatitis C, hepatitis B and HIV infection among drug users in a metha-done-maintenance programme. AIDS 1992;6:430-1.
3. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-55.
4. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antirctroviral therapy for HIV infection in 1996-recommendations of an international panel. JAMA 1996;276:146-54.
5. Yoshimura E, Hayashi J, Ueno K. No significant changes in levels of hepatitis C virus (HCV) RNA by competitive polymerase chain reaction in blood samples form patients with chronic HCV infection. Dig Dis Sci 1997;42:772-7.
6. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
7. Negro F, Abate ML, Mondardini A, et al. The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with Interferon. J Viral Hepat 1995;2:171-4.
8. Battegay M. Immunity to hepatitis C virus: a further piece of the puzzle. Hepatology 1996;24:961-3.
9. Greenway AL, Hertzog PJ, Devenish RJ, Dudley FJ, McMullen GL, Linnane AW. Immunolocalisation of interferon-alpha in hepatitis C patients and its correlation with response to interferon-alpha therapy. J Hepatol 1994;21:842-52.
10. Pirisi M, Fabris C, Toniutto P, et al. Endogenous interferon-a concentration and outcome of interferon treatment in patients with chronic hepatitis C. Dig Dis Sci 1997:42:767-71.